Megavitamin-B6 syndrome

Last updated
Megavitamin-B6 syndrome
Other namesVitamin B6 Excess, Hypervitaminosis B6, Vitamin B6 Toxicity [1] [2]
Specialty Neurology, toxicology
Symptoms Peripheral sensory neuropathy
Usual onsetGradual onset with slow progression, in the usual case of chronic vitamin B6 supplementation. [3]
DurationUsually, but not always, resolves within six months from the cessation of vitamin B6. [4]
CausesChronic vitamin B6 supplementation, or acute parenteral or oral over‐dosages of vitamin B6. [5] [4] [6] [7] [8]
Risk factors Impaired kidney function, parenteral nutrition [9]
Diagnostic method Serum testing for elevated levels of vitamin B6, testing of tendon reflexes, nerve conduction studies and electrodiagnostic testing. [10] [11]
Differential diagnosis Progressive mixed sensory or sensorimotor polyneuropathy of undetermined etiology. [12] [13]
TreatmentCessation of vitamin B6 supplementation. [14]
Prognosis Symptom progression for 2-6 weeks following cessation of vitamin B6, followed by gradual improvement. [14] [4] [15] [16]

Megavitamin-B6 syndrome, also known as hypervitaminosis B6, vitamin B6 toxicity, and vitamin B6 excess, [a] is a medical condition characterized by adverse effects resulting from excessive intake of vitamin B6. [1] [2] [22] Primarily affecting the nervous system, this syndrome manifests through symptoms such as peripheral sensory neuropathy, characterized by numbness, tingling, and burning sensations in the limbs. The condition is usually triggered by chronic dietary supplementation of vitamin B6 but can also result from acute over-dosages, whether orally or parenterally. [4] [5] [6]

Contents

The syndrome is notable not only for its impact on peripheral nerve function but also because of its generally, but not always, reversible nature upon cessation of vitamin B6 intake. Usually, but not always, cases resolve within six months after stopping the vitamin B6 supplementation, although some symptoms can intensify briefly after cessation—a phenomenon known as "coasting." Diagnosis typically involves serum tests to measure elevated levels of vitamin B6, along with nerve conduction studies and other neurodiagnostic evaluations. [4] [14] [15] [16]

This condition underscores the importance of moderation in the use of dietary supplements, highlighting that even substances generally safe at recommended dosages can lead to serious health issues if taken excessively. [23] The United States Institute of Medicine set a safe adult upper limit (UL) at 100 mg/day in 1998 [24] and has not revised that downward despite several other national agencies setting lower ULs, the most recent being the European Food Safety Authority revising its adult UL to 12 mg/day in 2023 [25] (see table).

Signs and symptoms

The predominant symptom is peripheral sensory neuropathy [26] [4] [6] [27] that is experienced as numbness, pins-and-needles and burning sensations (paresthesia) in a patient's limbs on both sides of their body. [14] [4] [13] [15] Patients may experience unsteadiness of gait, incoordination (ataxia), [15] [24] [4] [28] involuntary muscle movements (choreoathetosis) [10] the sensation of an electric zap in their bodies (Lhermitte's sign), [15] a heightened sensitivity to sense stimuli including photosensitivity (hyperesthesia), [4] [24] impaired skin sensation (hypoesthesia), [23] [14] numbness around the mouth, [23] [3] and gastrointestinal symptoms such as nausea and heartburn. [24] [29] The ability to sense vibrations and to sense one's position are diminished to a greater degree than pain or temperature. [23] [3] Skin lesions have also been reported. [24] [28] [30] [29] Megavitamin-B6 syndrome may also contribute to burning mouth syndrome. [31] [32] Potential psychiatric symptoms range from anxiety, depression, agitation, and cognitive deficits to psychosis. [33]

Symptom severity appears to be dose-dependent (higher doses cause more severe symptoms) [24] and the duration of supplementation with vitamin B6 before the onset of systems appears to be inversely proportional to the amount taken daily (the smaller the daily dosage, the longer it will take for symptoms to develop). [15] [4] [10] [12] [7] It is also possible that some individuals are more susceptible to the toxic effects of vitamin B6 than others. [4] Megavitamin-B6 syndrome has been reported in doses as low as 24 mg/day. [34]

Symptoms may also be dependent on the form of vitamin B6 taken in supplements. [27] [35] It has been proposed that vitamin B6 in supplements should be in pyridoxal or pyridoxal phosphate form rather than pyridoxine as these are thought to reduce the likelihood of toxicity. [27] [36] A tissue culture study, however, showed that all B6 vitamers that could be converted into active coenzymes (pyridoxal, pyridoxine and pyridoxamine) were neurotoxic at similar concentrations. [18] [37] It has been shown, in vivo, that supplementing with pyridoxal or pyridoxal phosphate increases pyridoxine concentrations in humans, meaning there are metabolic pathways from each vitamer of B6 to the all other forms. [38] [39] Consuming high amounts of vitamin B6 from food has not been reported to cause adverse effects. [24] [30] [40]

Early diagnosis and cessation of vitamin B6 supplementation can reduce the morbidity of the syndrome. [24] [12]

Cause

While vitamin B6 is water-soluble, it accumulates in the body. The half-life vitamin B6 is measured at around two to four weeks, [40] [41] it is stored in muscle, plasma, the liver, red blood cells and bound to proteins in tissues. [40] [42] [43]

Potential mechanisms

The common supplemental form of vitamin B6, pyridoxine, is similar to pyridine, which can be neurotoxic. Pyridoxine has limited transport across the blood–brain barrier, explaining why the central nervous system is spared. Cell bodies of motor fibers are located within the spinal cord, which is also restricted by the blood-brain barrier, explaining why motor impairment is rare. However, the dorsal root ganglia are located outside the blood-brain barrier, making them more susceptible. [23]

Pyridoxine is converted to pyridoxal phosphate via two enzymes, pyridoxal kinase and pyridoxine 5′-phosphate oxidase. High levels of pyridoxine can inhibit these enzymes. As pyridoxal phosphate is the active form of vitamin B6, this saturation of pyridoxine could mimic a deficiency of vitamin B6. [23] [27]

Tolerable upper limits

Several government agencies have reviewed the data on vitamin B6 supplementation and produced consumption upper limits with the desired goal of preventing sensory neuropathy from excessive amounts. Each agency developed its own criteria for usable studies concerning tolerable upper limits, and as such, the recommendations vary by agency. Between agencies, current tolerable upper limit guidelines vary from 10 mg per day to 100 mg per day. [40]

Daily vitamin B6 tolerable upper limits for adults as established by the agency
AgencyUpper limitNotesReference
National Health Service (NHS) United Kingdom10 mg/day [44]
Norwegian Scientific Committee for Food and Environment (VKM)25 mg/dayIn 2017 VKM proposed to raise this to 25 mg/day, it was previously 4.2 mg/day. [40]
Netherlands Food and Consumer Product Safety Authority  [ nl ] (NVWA)25 mg/daySupplements may only contain dosages of 21 mg/day. [45]
European Food Safety Authority 12 mg/day [25]
Ministry of Health, Labour and Welfare (厚生労働省, Kōsei-rōdō-shō) Japan40–60 mg/dayThe adult UL was set at 40–45 mg/day for women and 50–60 mg/day for men, with the lower values in those ranges for adults over 70 years of age [46]
National Health and Medical Research Council (NHMRC) Australia50 mg/dayThe Therapeutic Goods Administration requires a label warning about peripheral neuropathy if the daily dose is predicted to exceed 10 mg/day. [47] [48]
U.S. Institute of Medicine - Food and Nutrition Board100 mg/dayThe adult UL was set in 1998 and has not been updated as of 2024 [24]

Reviews of vitamin B6 related neuropathy cautioned that supplementation at doses greater than 50 mg per day for extended periods may be harmful and should be discouraged. [49] [50] In 2008, the Australian Complementary Medicines Evaluation Committee recommended warning statements appear on products containing daily doses of 50 mg or more vitamin B6 to avoid toxicity. [51]

The relationship between the amount of vitamin B6 consumed and the serum levels of those who consume it varies between individuals. [52] Some people may have high serum concentrations without neuropathy symptoms. [13] [53] [54] It is not known if inhalation of vitamin B6 while, for example, working with animal feed containing vitamin B6 is safe. [55]

Exceptions

High parenteral doses of vitamin B6 are used to treat isoniazid overdose with no adverse effects found, [4] although a preservative in parenteral vitamin B6 may cause transient worsening of metabolic acidosis. [4] High doses of vitamin B6 are used to treat gyromitra mushroom (false morel) poisoning, hydrazine exposure and homocystinuria [8] [56] Doses of 50 mg to 100 mg per day may also be used to treat pyridoxine deficient seizures and when patients are taking other medications that reduce vitamin B6. [14] Daily doses of 10 mg to 50 mg are recommended for patients undergoing hemodialysis. [14]

Outside of rare medical conditions, placebo-controlled studies have generally failed to show benefits of high doses of vitamin B6. [29] Reviews of supplementing with vitamin B6 have not found it to be effective at reducing swelling, reducing stress, producing energy, preventing neurotoxicity, or treating asthma. [23]

Diagnosis

The clinical hallmark of megavitamin-B6 syndrome is ataxia due to sensory polyneuropathy. Blood tests are performed to rule out other causes and to confirm an elevated level of vitamin B6 with an absence of hypophosphatasia. [14] [11] [12] [57] [58] Examination does not typically show signs of a motor deficit, dysfunction of the autonomic nervous system or impairment of the central nervous system, [4] [3] although in severe cases motor and autonomic impairment can occur. [14] [12] [59] When examined, patients typically have diminished reflexes (hyporeflexia), such as a diminished response when performing an ankle jerk reflex test. [14] [26] [3] Nerve conduction studies typically show normal motor conduction but a decrease in large sensory wave amplitude in the arms and legs. [26] [10] [14] [13] [3] Needle electromyography studies generally reveal no signs of denervation. [15]

Classification

Megavitamin-B6 syndrome is characterized mainly by degeneration of dorsal root ganglion axons and cell bodies, [60] [18] [23] [12] [10] [20] although it also affects the trigeminal ganglia. [23] [3] It is classified as a sensory ganglionopathy due to involvement of these ganglia. [61] [b] In electrodiagnostic testing, it has characteristic non-length-dependent abnormalities of sensory action potentials that occur globally, rather than distally decreasing sensory nerve action potential amplitudes. [57] Megavitamin-B6 syndrome is predominately a large fiber neuropathy characterized by sensory loss of joint position, vibration, and ataxia. [18] [26] Although it has characteristics of small fiber neuropathy in severe cases where there is impairment of pain, temperature, and autonomic functions. [62] [63] [14] [12] [59] [64] [17]

Treatment

The primary treatment for megavitamin-B6 syndrome is to stop taking supplemental vitamin B6. [14] Physical therapy, including vestibular rehabilitation, has been used in attempts to improve recovery following cessation of vitamin B6 supplementation. [51] [11] Medications such as amitriptyline have been used to help with neuropathic pain. [19]

In experimental tests using animal subjects, neurotrophic factors, specifically neurotrophin-3, were shown to potentially reverse the neuropathy caused from the vitamin B6 toxicity. [4] [18] With rats and mice, improvement has also been seen with 4-methylcatechol, a specific chicory extract, coffee and trigonelline. [65] [66] [67]

Prognosis

Other than with extremely high doses of vitamin B6, neurologic dysfunction improves following cessation of vitamin B6 supplementation and usually, but not always, resolves within six months. [3] [4] In cases of acute high doses, for example in people receiving daily doses of 2 grams of vitamin B6 per kilogram of body weight, symptoms may be irreversible and may additionally cause pseudoathetosis. [3] [15] [19] [16] [6] [8]

In the immediate 2–6 weeks following discontinuation of vitamin B6, patients may experience a symptom progression before gradual improvement begins. This is known as coasting and is encountered in other toxic neuropathies. [14] [4] [15] [16] A vitamin B6 substance dependency may exist in daily dosages of 200 mg or more, making a drug withdrawal effect possible when discontinued. [23]

See also

Notes

  1. ↑ While megavitamin-B6 syndrome, hypervitaminosis B6, vitamin B6 toxicity and vitamin B6 excess are officially recognized, megavitamin-B6 syndrome is the ICD-10 name. Before the adoption of a recognized standard, ad-hoc terms for this appear in literature, often vitamin B6 and its most common supplemental vitamer, pyridoxine, are used interchangeably. Some other terms include vitamin B6 overdose, [17] pyridoxine abuse, [18] [19] pyridoxine megavitamosis, [12] pyridoxine poisoning, [20] and pyridoxine neuropathy. [21]
  2. ↑ The terms sensory ganglionopathy and sensory neuronopathy are interchangeable. [61]

Related Research Articles

<span class="mw-page-title-main">Riboflavin</span> Vitamin, dietary supplement, and yellow food dye

Riboflavin, also known as vitamin B2, is a vitamin found in food and sold as a dietary supplement. It is essential to the formation of two major coenzymes, flavin mononucleotide and flavin adenine dinucleotide. These coenzymes are involved in energy metabolism, cellular respiration, and antibody production, as well as normal growth and development. The coenzymes are also required for the metabolism of niacin, vitamin B6, and folate. Riboflavin is prescribed to treat corneal thinning, and taken orally, may reduce the incidence of migraine headaches in adults.

Vitamin B<sub>6</sub> Class of chemically related vitamins

Vitamin B6 is one of the B vitamins, and is an essential nutrient for humans. The term essential nutrient refers to a group of six chemically similar compounds, i.e., "vitamers", which can be interconverted in biological systems. Its active form, pyridoxal 5′-phosphate, serves as a coenzyme in more than 140 enzyme reactions in amino acid, glucose, and lipid metabolism.

Vitamin deficiency is the condition of a long-term lack of a vitamin. When caused by not enough vitamin intake it is classified as a primary deficiency, whereas when due to an underlying disorder such as malabsorption it is called a secondary deficiency. An underlying disorder can have 2 main causes:

Paresthesia, also known as pins and needles, is an abnormal sensation of the skin with no apparent physical cause. Paresthesia may be transient or chronic, and may have many possible underlying causes. Paresthesias are usually painless and can occur anywhere on the body, but most commonly occur in the arms and legs.

<span class="mw-page-title-main">Peripheral neuropathy</span> Nervous system disease affecting nerves beyond the brain and spinal cord

Peripheral neuropathy, often shortened to neuropathy, refers to damage or disease affecting the nerves. Damage to nerves may impair sensation, movement, gland function, and/or organ function depending on which nerve fibers are affected. Neuropathies affecting motor, sensory, or autonomic nerve fibers result in different symptoms. More than one type of fiber may be affected simultaneously. Peripheral neuropathy may be acute or chronic, and may be reversible or permanent.

<span class="mw-page-title-main">Polyneuropathy</span> Any disease affecting peripheral nerves on both sides of the body

Polyneuropathy is damage or disease affecting peripheral nerves in roughly the same areas on both sides of the body, featuring weakness, numbness, and burning pain. It usually begins in the hands and feet and may progress to the arms and legs and sometimes to other parts of the body where it may affect the autonomic nervous system. It may be acute or chronic. A number of different disorders may cause polyneuropathy, including diabetes and some types of Guillain–Barré syndrome.

<span class="mw-page-title-main">Hypervitaminosis</span> Medical condition

Hypervitaminosis is a condition of abnormally high storage levels of vitamins, which can lead to various symptoms as over excitement, irritability, or even toxicity. Specific medical names of the different conditions are derived from the given vitamin involved: an excess of vitamin A, for example, is called hypervitaminosis A. Hypervitaminoses are primarily caused by fat-soluble vitamins, as these are stored by the body for longer than the water-soluble vitamins.

<span class="mw-page-title-main">Pyridoxine</span> Chemical compound

Pyridoxine (PN) is a form of vitamin B6 found commonly in food and used as a dietary supplement. As a supplement it is used to treat and prevent pyridoxine deficiency, sideroblastic anaemia, pyridoxine-dependent epilepsy, certain metabolic disorders, side effects or complications of isoniazid use, and certain types of mushroom poisoning. It is used by mouth or by injection.

<span class="mw-page-title-main">Alcoholic polyneuropathy</span> Medical condition

Alcoholic polyneuropathy is a neurological disorder in which peripheral nerves throughout the body malfunction simultaneously. It is defined by axonal degeneration in neurons of both the sensory and motor systems and initially occurs at the distal ends of the longest axons in the body. This nerve damage causes an individual to experience pain and motor weakness, first in the feet and hands and then progressing centrally. Alcoholic polyneuropathy is caused primarily by chronic alcoholism; however, vitamin deficiencies are also known to contribute to its development. This disease typically occurs in chronic alcoholics who have some sort of nutritional deficiency. Treatment may involve nutritional supplementation, pain management, and abstaining from alcohol.

<span class="mw-page-title-main">Neuritis</span> Inflammation of a nerve or generally any part of the nervous system

Neuritis, from the Greek νεῦρον), is inflammation of a nerve or the general inflammation of the peripheral nervous system. Inflammation, and frequently concomitant demyelination, cause impaired transmission of neural signals and leads to aberrant nerve function. Neuritis is often conflated with neuropathy, a broad term describing any disease process which affects the peripheral nervous system. However, neuropathies may be due to either inflammatory or non-inflammatory causes, and the term encompasses any form of damage, degeneration, or dysfunction, while neuritis refers specifically to the inflammatory process.

<span class="mw-page-title-main">Hypervitaminosis A</span> Toxic effects of ingesting too much vitamin A

Hypervitaminosis A refers to the toxic effects of ingesting too much preformed vitamin A. Symptoms arise as a result of altered bone metabolism and altered metabolism of other fat-soluble vitamins. Hypervitaminosis A is believed to have occurred in early humans, and the problem has persisted throughout human history. Toxicity results from ingesting too much preformed vitamin A from foods, supplements, or prescription medications and can be prevented by ingesting no more than the recommended daily amount.

Megavitamin therapy is the use of large doses of vitamins, often many times greater than the recommended dietary allowance (RDA) in the attempt to prevent or treat diseases. Megavitamin therapy is typically used in alternative medicine by practitioners who call their approach orthomolecular medicine. Vitamins are useful in preventing and treating illnesses specifically associated with dietary vitamin shortfalls, but the conclusions of medical research are that the broad claims of disease treatment by advocates of megavitamin therapy are unsubstantiated by the available evidence. It is generally accepted that doses of any vitamin greatly in excess of nutritional requirements will result either in toxicity or in the excess simply being metabolised; thus evidence in favour of vitamin supplementation supports only doses in the normal range. Critics have described some aspects of orthomolecular medicine as food faddism or even quackery. Research on nutrient supplementation in general suggests that some nutritional supplements might be beneficial, and that others might be harmful; several specific nutritional therapies are associated with an increased likelihood of the condition they are meant to prevent.

Toxic and nutritional optic neuropathy is a group of medical disorders defined by visual impairment due to optic nerve damage secondary to a toxic substance and/or nutritional deficiency. The causes of these disorders are various, but they are linked by shared signs and symptoms. In several of these disorders, both toxic and nutritional factors play a role, acting synergistically.

<span class="mw-page-title-main">Copper deficiency</span> Insufficient level of copper in the body, leading to anaemia and nervous symptoms

Copper deficiency, or hypocupremia, is defined as insufficient copper to meet the body's needs, or as a serum copper level below the normal range. Symptoms may include fatigue, decreased red blood cells, early greying of the hair, and neurological problems presenting as numbness, tingling, muscle weakness, and ataxia. The neurodegenerative syndrome of copper deficiency has been recognized for some time in ruminant animals, in which it is commonly known as "swayback". Copper deficiency can manifest in parallel with vitamin B12 and other nutritional deficiencies.

A vitamer is any of the related forms in which some vitamin occurs. Each vitamer of a particular vitamin is a compound that performs the functions of that vitamin and prevents the symptoms of deficiency of the vitamin.

<span class="mw-page-title-main">Pyridoxine-dependent epilepsy</span> Medical condition

Pyridoxine-dependent epilepsy (PDE) is a rare genetic disorder characterized by intractable seizures in the prenatal and neonatal period. The disorder was first recognized in the 1950s, with the first description provided by Hunt et al. in 1954. More recently, pathogenic variants within the ALDH7A1 gene have been identified to cause PDE.

<span class="mw-page-title-main">Nutritional neuroscience</span> Scientific discipline

Nutritional neuroscience is the scientific discipline that studies the effects various components of the diet such as minerals, vitamins, protein, carbohydrates, fats, dietary supplements, synthetic hormones, and food additives have on neurochemistry, neurobiology, behavior, and cognition.

Sexual anhedonia, also known as pleasure dissociative orgasmic disorder, is a condition in which an individual cannot feel pleasure from an orgasm. It is thought to be a variant of hypoactive sexual desire disorder.

<span class="mw-page-title-main">Metadoxine</span> Medication used for alcohol intoxication

Metadoxine, also known as pyridoxine-pyrrolidone carboxylate, is a drug used to treat chronic and acute alcohol intoxication. Metadoxine accelerates alcohol clearance from the blood.

Mitochondrial optic neuropathies are a heterogenous group of disorders that present with visual disturbances resultant from mitochondrial dysfunction within the anatomy of the Retinal Ganglion Cells (RGC), optic nerve, optic chiasm, and optic tract. These disturbances are multifactorial, their aetiology consisting of metabolic and/or structural damage as a consequence of genetic mutations, environmental stressors, or both. The three most common neuro-ophthalmic abnormalities seen in mitochondrial disorders are bilateral optic neuropathy, ophthalmoplegia with ptosis, and pigmentary retinopathy.

References

  1. 1 2 Bell, Daniel J. "Vitamin B6 excess". Radiopaedia. Archived from the original on 2019-10-24. Retrieved 2019-12-01. Vitamin B6 excess (hypervitaminosis B6) is caused by excessive consumption of supplemental pyridoxine, which is used as a therapeutic agent for several conditions.
  2. 1 2 "Hypervitaminosis B6 (Concept Id: C0238176) - MedGen - NCBI". MedGen. National Center for Biotechnology Information (NCBI). Archived from the original on 2019-11-05. Retrieved 2019-12-02.
  3. 1 2 3 4 5 6 7 8 9 Koontz, Daniel W; Maddux, Brian; Katirji, Bashar (2004). "Evaluation of a Patient Presenting With Rapidly Progressive Sensory Ataxia". Journal of Clinical Neuromuscular Disease. 6 (1): 40–47. doi:10.1097/01.cnd.0000133065.28161.00. ISSN   1522-0443. PMID   19078751. S2CID   26316070.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Lheureux, P.; Penaloza, A.; Gris, M. (2005). "Pyridoxine in clinical toxicology: A review". European Journal of Emergency Medicine. 12 (2): 78–85. doi:10.1097/00063110-200504000-00007. PMID   15756083. S2CID   39197646.
  5. 1 2 Silva, C D; D'Cruz, D P (2006). "Pyridoxine toxicity courtesy of your local health food store". Annals of the Rheumatic Diseases. 65 (12): 1666–1667. doi:10.1136/ard.2006.054213. ISSN   0003-4967. PMC   1798481 . PMID   17105856. Pyridoxine toxicity is a recognised cause of sensory neuropathy. Schaumburg et al described sensory neuropathy after pyridoxine misuse in 1983. It can occur with chronic use of pyridoxine supplementation over several years, and also with acute over-dosage with parenteral pyridoxine.
  6. 1 2 3 4 James W. Albers; Stanley Berent (15 August 2005). Neurobehavioral Toxicology: Neurological and Neuropsychological Perspectives, Volume II: Peripheral Nervous System. Taylor & Francis. pp. 2–. ISBN   978-1-135-42106-9.
  7. 1 2 Kennedy, Ashleigh; Schaeffer, Tammi (2016). "Pyridoxine". Critical Care Toxicology. pp. 1–4. doi:10.1007/978-3-319-20790-2_174-1. ISBN   978-3-319-20790-2.
  8. 1 2 3 London, Zachary; Albers, James W. (2007). "Toxic Neuropathies Associated with Pharmaceutic and Industrial Agents". Neurologic Clinics. 25 (1): 257–276. doi:10.1016/j.ncl.2006.10.001. ISSN   0733-8619. PMID   17324727.
  9. ↑ Mikalunas, Vida; Fitzgerald, Kathleen; Rubin, Halina; McCarthy, Roberta; Craig, Robert M. (2001). "Abnormal Vitamin Levels in Patients Receiving Home Total Parenteral Nutrition". Journal of Clinical Gastroenterology. 33 (5): 393–396. doi:10.1097/00004836-200111000-00010. ISSN   0192-0790. PMID   11606856. S2CID   12384721.
  10. 1 2 3 4 5 Donofrio, Peter D. (2005). "Evaluating the Patient With Peripheral Neuropathy" (PDF). Numbness, Tingling, Pain, and Weakness: A Basic Course in Electrodiagnostic Medicine. Monterey, California: AANEM 52nd Annual Scientific Meeting. Archived from the original (PDF) on 2022-03-31. Retrieved 2019-11-16.
  11. 1 2 3 Rohitha Moudgal; Shahla Hosseini; Patricia Colapietro; Oluwole Awosika (2018-04-25). "Vitamin B6 Toxicity Revisited: A Case of Reversible Pyridoxine-associated Neuropathy and Disequilibrium. (P4.021)". Neurology. 90 (15 Supplement). Archived from the original on 2019-10-20. Retrieved 2019-11-16.
  12. 1 2 3 4 5 6 7 8 Ahmed, Aiesha; Velazquez-Rodriguez, Yadira; Kaur, Divpreet (2014-04-08). "When Expected Turns Unexpected: A Case of Subacute Progressive Weakness and Paresthesias of the Distal Lower Extremities Following a Brief Diarrheal Episode. (P6.111)". Neurology. 82 (10 Supplement): P6.111. Archived from the original on 2019-09-27. Retrieved 2019-11-26.
  13. 1 2 3 4 Scott, K.; Zeris, S.; Kothari, M. J. (2008). "Elevated B6 levels and peripheral neuropathies". Electromyography and Clinical Neurophysiology. 48 (5): 219–23. PMID   18754531.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Hammond, N.; Wang, Y.; Dimachkie, M.; Barohn, R. (2013). "Nutritional Neuropathies". Neurologic Clinics. 31 (2): 477–489. doi:10.1016/j.ncl.2013.02.002. PMC   4199287 . PMID   23642720.
  15. 1 2 3 4 5 6 7 8 9 Bromberg, Mark B. (2000). "Peripheral Neurotoxic Disorders". Neurologic Clinics. 18 (3): 681–694. doi:10.1016/S0733-8619(05)70218-8. ISSN   0733-8619. PMID   10873238.
  16. 1 2 3 4 Saleh, Firas G.; Seidman, Roberta J. (2003-12-01). "Drug-Induced Myopathy and Neuropathy". Journal of Clinical Neuromuscular Disease. 5 (2): 81–91. doi:10.1097/00131402-200312000-00003. PMID   19078725. S2CID   31440274.
  17. 1 2 Sène, Damien (2018). "Small fiber neuropathy: Diagnosis, causes, and treatment". Joint Bone Spine. 85 (5): 553–559. doi:10.1016/j.jbspin.2017.11.002. ISSN   1297-319X. PMID   29154979. S2CID   43023310.
  18. 1 2 3 4 5 Hlubocky, Ales; Smith, Benn E. (2014). "Dorsal Root Ganglion Disorders". Neuromuscular Disorders in Clinical Practice. pp. 467–491. doi:10.1007/978-1-4614-6567-6_23. ISBN   978-1-4614-6566-9.
  19. 1 2 3 Lacerna, Rhodora A.; Chien, Chloe; Yeh, Shing-Shing (2003). "Paresthesias Developing in an Elderly Patient after Chronic Usage of Nitrofurantoin and Vitamin B6". Journal of the American Geriatrics Society. 51 (12): 1822–1823. doi:10.1046/j.1532-5415.2003.51572_8.x. PMID   14687374. S2CID   26337220.
  20. 1 2 Donofrio, Peter Daniel (2000). "Electrophysiological Evaluations". Neurologic Clinics. 18 (3): 601–613. doi:10.1016/S0733-8619(05)70213-9. ISSN   0733-8619. PMID   10873233. Archived from the original on 2020-01-17. Retrieved 2019-12-01.
  21. ↑ Schaeppi, U.; Krinke, G. (1982). "Pyridoxine neuropathy: Correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6". Agents and Actions. 12 (4): 575–582. doi:10.1007/BF01965944. ISSN   0065-4299. PMID   7180742. S2CID   30742144.
  22. ↑ de Onis, Mercedes; Zeitlhuber, Julia; Martínez-Costa, Cecilia (2016). "Nutritional disorders in the proposed 11th revision of the International Classification of Diseases: feedback from a survey of stakeholders". Public Health Nutrition. 19 (17): 3135–3141. doi:10.1017/S1368980016001427. ISSN   1368-9800. PMC   5217466 . PMID   27293047.
  23. 1 2 3 4 5 6 7 8 9 10 Gangsaas, Ingvild (1995). "Dispelling the Myths of Vitamin B6" (PDF). Nutrition Bytes. 1 (1). ISSN   1548-4327. Archived (PDF) from the original on 2019-10-21. Retrieved 2019-11-16.
  24. 1 2 3 4 5 6 7 8 9 "Vitamin B6 — Health Professional Fact Sheet". National Institutes of Health Office Dietary Supplements. U.S. Department of Health and Human Services. Archived from the original on 2019-11-25. Retrieved 2019-12-02.
  25. 1 2 Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst KI, et al. (May 2023). "Scientific opinion on the tolerable upper intake level for vitamin B6". EFSA J. 21 (5): e08006. doi:10.2903/j.efsa.2023.8006. PMC   10189633 . PMID   37207271.
  26. 1 2 3 4 Callizot, Noëlle; Poindron, Philippe (2008). "Pyridoxine-Induced Peripheral Neuropathy". New Animal Models of Human Neurological Diseases. Biovalley Monographs. pp. 66–80. doi:10.1159/000117724. ISBN   978-3-8055-8405-0. ....a specific large-fibre neuropathy (with severe loss of proprioceptive function) is encountered clinically after vitamin B6 (pyridoxine).... All subjects showed paraesthesia and numbness as well as ataxia. The clinical examination showed a large sensory deficit with Achilles' reflex loss, associated with Romberg's signs (loss of proprioceptive control in which increased unsteadiness occurs when standing with the eyes closed compared with standing with the eyes open). The electromyographic examination showed a large sensory wave amplitude decrease but no change in the motor conduction.... small fibres were also involved as shown by the decreased SNCV and the altered thermosensitivity detected in the hot plate test. The same signs are observed in humans suffering from pyridoxine-induced neuropathy.
  27. 1 2 3 4 Wilmshurst, Jo M.; Ouvrier, Robert A.; Ryan, Monique M. (2019). "Peripheral nerve disease secondary to systemic conditions in children". Therapeutic Advances in Neurological Disorders. 12: 175628641986636. doi:10.1177/1756286419866367. PMC   6691669 . PMID   31447934.
  28. 1 2 Stover, Patrick J; Field, Martha S (2015). "Vitamin B-6". Advances in Nutrition. 6 (1): 132–133. doi:10.3945/an.113.005207. ISSN   2161-8313. PMC   4288272 . PMID   25593152.
  29. 1 2 3 Chawla, Jasvinder; Kvarnberg, David (2014). "Hydrosoluble vitamins". Neurologic Aspects of Systemic Disease Part II. Handbook of Clinical Neurology. Vol. 120. pp. 891–914. doi:10.1016/B978-0-7020-4087-0.00059-0. ISBN   978-0-7020-4087-0. ISSN   0072-9752. PMID   24365359.
  30. 1 2 Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline (1998). "Vitamin B6". Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US). Archived from the original on 2021-02-27. Retrieved 2019-12-02.{{cite book}}: CS1 maint: multiple names: authors list (link)
  31. ↑ Dieb, Wisam; Boucher, Yves (2017). "Burning Mouth Syndome and Vitamin B6". Pain Medicine. 18 (8): 1593–1594. doi: 10.1093/pm/pnw345 . ISSN   1526-2375. PMID   28371806.
  32. ↑ Dieb, Wisam; Moreau, Nathan; Rochefort, Juliette; Boucher, Yves (2016). "Role of vitamin B6 in idiopathic burning mouth syndrome: some clinical observations" (PDF). Médecine Buccale Chirurgie Buccale. 23 (2): 77–83. doi: 10.1051/mbcb/2016038 . ISSN   1273-2761. Archived (PDF) from the original on 2018-12-06. Retrieved 2019-11-16.
  33. ↑ Hani R. Khouzam; Doris Tiu Tan; Tirath S. Gill (9 March 2007). Handbook of Emergency Psychiatry E-Book. Elsevier Health Sciences. pp. 65–. ISBN   978-0-323-07661-6.
  34. ↑ De Kruijk, J. R.; Notermans, N. C. (2005). "Sensory disturbances caused by multivitamin preparations". Nederlands Tijdschrift voor Geneeskunde. 149 (46): 2541–4. PMID   16320661.
  35. ↑ Levine, Seymour; Saltzman, Arthur (2004). "Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet". Journal of Applied Toxicology. 24 (6): 497–500. doi:10.1002/jat.1007. ISSN   0260-437X. PMID   15558839. S2CID   8280774.
  36. ↑ Vrolijk, M. F.; Opperhuizen, A.; Jansen EHJM; Hageman, G. J.; Bast, A.; Haenen GRMM (2017). "The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function". Toxicology in Vitro. 44: 206–212. Bibcode:2017ToxVi..44..206V. doi:10.1016/j.tiv.2017.07.009. PMID   28716455.
  37. ↑ Windebank, Anthony J. (1985). "Neurotoxicity of pyridoxine analogs is related to coenzyme structure". Neurochemical Pathology. 3 (3): 159–167. doi:10.1007/BF02834268. ISSN   0734-600X. PMID   4094726.
  38. ↑ Hadtstein, Felix; Vrolijk, Misha (2021). "Vitamin B-6-Induced Neuropathy: Exploring the Mechanisms of Pyridoxine Toxicity". Advances in Nutrition. 12 (5): 1911–1929. doi: 10.1093/advances/nmab033 . PMC   8483950 . PMID   33912895.
  39. ↑ Ramos, Rúben J.; Albersen, Monique; Vringer, Esmee; Bosma, Marjolein; Zwakenberg, Susan; Zwartkruis, Fried; Jans, Judith J.M.; Verhoeven-Duif, Nanda M. (2019). "Discovery of pyridoxal reductase activity as part of human vitamin B6 metabolism". Biochimica et Biophysica Acta (BBA) - General Subjects. 1863 (6): 1088–1098. doi: 10.1016/j.bbagen.2019.03.019 . ISSN   0304-4165. PMID   30928491. S2CID   89618004.
  40. 1 2 3 4 5 Assessment of vitamin B6 intake in relation to tolerable upper intake levels. Opinion of the Panel on Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientific Committee for Food Safety (PDF). Oslo, Norway. ISBN   978-82-8259-260-4. Archived from the original (PDF) on 2019-11-17. Retrieved 2019-12-07. Eighty to ninety percent of vitamin B6 in the body is found in muscles and estimated body stores in adults amount to about 170 mg with a half-life of 25-33 days... Intakes of vitamin B6 from the diet alone have not been reported to cause adverse effects... (See: Table 2.2.1-1 for summary of available upper intake levels for vitamin B6.
  41. ↑ Kennedy, Ashleigh; Schaeffer, Tammi (2016). "Pyridoxine". Critical Care Toxicology. pp. 1–4. doi:10.1007/978-3-319-20790-2_174-1. ISBN   978-3-319-20790-2. The half-life of pyridoxine is up to 20 days.
  42. ↑ Reeds, Karen (2019-03-04). Ann Ehrenberger, Kristen; Haushofer, Lisa (eds.). "Vitamin B Complexities". H-Nutrition. Archived from the original on 2021-05-12. Retrieved 2019-11-16.
  43. ↑ Institute of Medicine (29 September 2006). Dietary Reference Intakes: The Essential Guide to Nutrient Requirements. National Academies Press. pp. 184–. ISBN   978-0-309-15742-1. Archived from the original on 19 March 2024. Retrieved 7 December 2019.
  44. ↑ "Vitamins and minerals - B vitamins and folic acid - NHS". National Health Service . 3 March 2017. Archived from the original on 2019-10-21. Retrieved 2019-11-01.
  45. ↑ "Advies van BuRO over vitamine B6 uit voedingssupplementen". Netherlands Food and Consumer Product Safety Authority (in Dutch). 2016-12-16. Archived from the original on 2019-12-07. Retrieved 2019-12-07.
  46. ↑ "Overview of Dietary Reference Intakes for Japanese" (PDF). Ministry of Health, Labour and Welfare (Japan). 2015. Archived from the original (PDF) on 2021-08-19. Retrieved 19 August 2021.
  47. ↑ "Vitamin B6". Nutrient Reference Values for Australia and New Zealand. National Health and Medication Research Council (NHMRC). 2014-03-17. Archived from the original on 2019-03-04. Retrieved 2019-12-02.
  48. ↑ "Peripheral neuropathy with supplementary vitamin B6 (pyridoxine)". Therapeutic Goods Administration . Australian Government . Retrieved 5 January 2025.
  49. ↑ Ghavanini, A. A.; Kimpinski, K. (2014). "Revisiting the evidence for neuropathy caused by pyridoxine deficiency and excess". Journal of Clinical Neuromuscular Disease. 16 (1): 25–31. doi:10.1097/CND.0000000000000049. PMID   25137514. S2CID   205557831.
  50. ↑ Bender, David A. (1997). "Vitamin B6". Nutrition & Food Science. 97 (4): 128–133. doi:10.1108/00346659710179642. ISSN   0034-6659.
  51. 1 2 Adverse Drug Reactions Advisory Committee (ADRAC) and the Office of Medicine Safety Monitoring (OMSM) of the TGA. (2008-08-01). "High-dose vitamin B6 may cause peripheral neuropathy". Australian Adverse Drug Reactions Bulletin. 27 (4). Archived from the original on 2017-09-23.
  52. ↑ Vrolijk, Misha F; Hageman, Geja J; van de Koppel, Sonja; van Hunsel, Florence; Bast, Aalt (2020). "Inter-individual differences in pharmacokinetics of vitamin B6: A possible explanation of different sensitivity to its neuropathic effects". PharmaNutrition. 12: 100188. doi: 10.1016/j.phanu.2020.100188 . ISSN   2213-4344. S2CID   216338587.
  53. ↑ Van Hunsel, Florence; Van De Koppel, Sonja; Van Puijenbroek, Eugène; Kant, Agnes (2018). "Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases" (PDF). Drug Safety. 41 (9): 859–869. doi:10.1007/s40264-018-0664-0. PMID   29737502. S2CID   13685351. Archived (PDF) from the original on 2022-04-08. Retrieved 2021-09-10.
  54. ↑ Critcher, Matt S.; Sobczynska-Malefora, Agata (2015-09-15). "Vitamin B6: low and very high concentrations in hospital patients" (PDF). The Biomedical Scientist. Archived from the original (PDF) on 2022-04-08. Retrieved 2019-11-16.
  55. ↑ "Scientific Opinion on the safety and efficacy of vitamin B6(pyridoxine hydrochloride) as a feed additive for all animal species". EFSA Journal. 9 (5): 2171. 2011. doi: 10.2903/j.efsa.2011.2171 . ISSN   1831-4732.
  56. ↑ Echaniz-Laguna, Andoni; Mourot-Cottet, Rachel; Noel, Esther; Chanson, Jean-Baptiste (2018). "Regressive pyridoxine-induced sensory neuronopathy in a patient with homocystinuria". BMJ Case Reports. 2018: bcr–2018–225059. doi:10.1136/bcr-2018-225059. ISSN   1757-790X. PMC   6040505 . PMID   29954767.
  57. 1 2 Gdynia, Hans-Jürgen; Müller, Timo; Sperfeld, Anne-Dorte; Kühnlein, Peter; Otto, Markus; Kassubek, Jan; Ludolph, Albert C. (2008). "Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6". Neuromuscular Disorders. 18 (2): 156–158. doi:10.1016/j.nmd.2007.09.009. ISSN   0960-8966. PMID   18060778. S2CID   7370460.
  58. ↑ Whyte, M P; Mahuren, J D; Vrabel, L A; Coburn, S P (1985). "Markedly increased circulating pyridoxal-5'-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism". Journal of Clinical Investigation. 76 (2): 752–756. doi:10.1172/JCI112031. ISSN   0021-9738. PMC   423894 . PMID   4031070.
  59. 1 2 Bacharach, Rae; Lowden, Max; Ahmed, Aiesha (2017). "Pyridoxine Toxicity Small Fiber Neuropathy With Dysautonomia". Journal of Clinical Neuromuscular Disease. 19 (1): 43–46. doi:10.1097/CND.0000000000000172. ISSN   1522-0443. PMID   28827489. S2CID   13734173.
  60. ↑ Bashar Katirji; Henry J. Kaminski; Robert L. Ruff (11 October 2013). Neuromuscular Disorders in Clinical Practice. Springer Science & Business Media. pp. 468–. ISBN   978-1-4614-6567-6. Archived from the original on 19 March 2024. Retrieved 7 December 2019.
  61. 1 2 Sheikh, S. I.; Amato, A. A. (2010). "The dorsal root ganglion under attack: the acquired sensory ganglionopathies". Practical Neurology. 10 (6): 326–334. doi:10.1136/jnnp.2010.230532. ISSN   1474-7758. PMID   21097829. S2CID   38755244.
  62. ↑ Perry, Tracy Ann; Weerasuriya, Ananda; Mouton, Peter R.; Holloway, Harold W.; Greig, Nigel H. (2004). "Pyridoxine-induced toxicity in rats: A stereological quantification of the sensory neuropathy". Experimental Neurology. 190 (1): 133–. doi:10.1016/j.expneurol.2004.07.013. PMID   15473987. S2CID   25543353. Archived from the original on 2021-05-12. Retrieved 2020-06-06.
  63. ↑ Misra, UshaKant; Kalita, Jayantee; Nair, PradeepP (2008). "Diagnostic approach to peripheral neuropathy". Annals of Indian Academy of Neurology. 11 (2): 89–97. doi: 10.4103/0972-2327.41875 . ISSN   0972-2327. PMC   2771953 . PMID   19893645.
  64. ↑ Bakkers, Mayienne (2015). Small fibers, big troubles: diagnosis and implications of small fiber neuropathy (PDF). Datawyse / Universitaire Pers Maastricht. Archived (PDF) from the original on 2019-10-24. Retrieved 2019-12-01.
  65. ↑ Hasannejad, Farkhonde; Ansar, Malek Moein; Rostampour, Mohammad; Mahdavi Fikijivar, Edris; Khakpour Taleghani, Behrooz (2019). "Improvement of pyridoxine-induced peripheral neuropathy by Cichorium intybus hydroalcoholic extract through GABAergic system". The Journal of Physiological Sciences. 69 (3): 465–476. doi: 10.1007/s12576-019-00659-8 . ISSN   1880-6546. PMC   10718042 . PMID   30712095. S2CID   59541162.
  66. ↑ Callizot, Noelle; Warter, Jean-Marie; Poindron, Philippe (2001). "Pyridoxine-Induced Neuropathy in Rats: A Sensory Neuropathy That Responds to 4-Methylcatechol". Neurobiology of Disease. 8 (4): 626–635. doi:10.1006/nbdi.2001.0408. ISSN   0969-9961. PMID   11493027. S2CID   30526195.
  67. ↑ Hong, Bin Na; Yi, Tae Hoo; Kim, Sun Yeou; Kang, Tong Ho (2009). "High-Dosage Pyridoxine-Induced Auditory Neuropathy and Protection with Coffee in Mice". Biological & Pharmaceutical Bulletin. 32 (4): 597–603. doi: 10.1248/bpb.32.597 . ISSN   0918-6158. PMID   19336890.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.